Literature DB >> 17826033

PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.

Jing Fang1, Min Ding, Lily Yang, Ling-Zhi Liu, Bing-Hua Jiang.   

Abstract

PI3K pathway exerts its function through its downstream molecule AKT in regulating various cell functions including cell proliferation, cell transformation, cell apoptosis, tumor growth and angiogenesis. PTEN is an inhibitor of PI3K, and its loss or mutation is common in human prostate cancer. But the direct role and mechanism of PI3K/PTEN signaling in regulating angiogenesis and tumor growth in vivo remain to be elucidated. In this study, by using chicken chorioallantoic membrane (CAM) and in nude mice models, we demonstrated that inhibition of PI3K activity by LY294002 decreased PC-3 cells-induced angiogenesis. Reconstitution of PTEN, the molecular inhibitor of PI3K in PC-3 cells inhibited angiogenesis and tumor growth. Immunohistochemical staining indicated that PTEN expression suppressed HIF-1alpha, VEGF and PCNA expression in the tumor xenographs. Similarly, expression of AKT dominant negative mutant also inhibited angiogenesis and tumor growth, and decreased the expression of HIF-1alpha and VEGF in the tumor xenographs. These results suggest that inhibition of PI3K signaling pathway by PTEN inhibits tumor angiogenesis and tumor growth. In addition, we found that AKT is the downstream target of PI3K in controlling angiogenesis and tumor growth, and PTEN could inhibit angiogenesis by regulating the expression of HIF-1 and VEGF expression through AKT activation in PC-3 cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17826033      PMCID: PMC2094004          DOI: 10.1016/j.cellsig.2007.07.025

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  36 in total

Review 1.  Molecular genetics of prostate cancer.

Authors:  C Abate-Shen; M M Shen
Journal:  Genes Dev       Date:  2000-10-01       Impact factor: 11.361

2.  HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression.

Authors:  E Laughner; P Taghavi; K Chiles; P C Mahon; G L Semenza
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

3.  Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.

Authors:  H Zhong; K Chiles; D Feldser; E Laughner; C Hanrahan; M M Georgescu; J W Simons; G L Semenza
Journal:  Cancer Res       Date:  2000-03-15       Impact factor: 12.701

Review 4.  AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation.

Authors:  T O Chan; S E Rittenhouse; P N Tsichlis
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

5.  Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase.

Authors:  Marcella Priulla; Angela Calastretti; Paola Bruno; Amalia Azzariti; Azzariti Amalia; Angelo Paradiso; Gianfranco Canti; Angelo Nicolin
Journal:  Prostate       Date:  2007-05-15       Impact factor: 4.104

6.  Impairment of erbB1 receptor and fluid-phase endocytosis and associated mitogenic signaling by inositol hexaphosphate in human prostate carcinoma DU145 cells.

Authors:  X Zi; R P Singh; R Agarwal
Journal:  Carcinogenesis       Date:  2000-12       Impact factor: 4.944

7.  Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1.

Authors:  B H Jiang; G Jiang; J Z Zheng; Z Lu; T Hunter; P K Vogt
Journal:  Cell Growth Differ       Date:  2001-07

8.  Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells.

Authors:  B H Jiang; J Z Zheng; M Aoki; P K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

9.  Loss of PTEN facilitates HIF-1-mediated gene expression.

Authors:  W Zundel; C Schindler; D Haas-Kogan; A Koong; F Kaper; E Chen; A R Gottschalk; H E Ryan; R S Johnson; A B Jefferson; D Stokoe; A J Giaccia
Journal:  Genes Dev       Date:  2000-02-15       Impact factor: 11.361

10.  Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.

Authors:  C Blancher; J W Moore; N Robertson; A L Harris
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

View more
  67 in total

1.  Loss of PTEN permits CXCR4-mediated tumorigenesis through ERK1/2 in prostate cancer cells.

Authors:  Mahandranauth A Chetram; Valerie Odero-Marah; Cimona V Hinton
Journal:  Mol Cancer Res       Date:  2010-11-12       Impact factor: 5.852

2.  MicroRNA-21 promotes glioma cell proliferation and inhibits senescence and apoptosis by targeting SPRY1 via the PTEN/PI3K/AKT signaling pathway.

Authors:  Chang Chai; Lai-Jun Song; Shuang-Yin Han; Xi-Qing Li; Ming Li
Journal:  CNS Neurosci Ther       Date:  2018-01-05       Impact factor: 5.243

3.  Q39, a quinoxaline 1,4-Di-N-oxide derivative, inhibits hypoxia-inducible factor-1α expression and the Akt/mTOR/4E-BP1 signaling pathway in human hepatoma cells.

Authors:  Qinjie Weng; Jun Zhang; Ji Cao; Qing Xia; Duoduo Wang; Yongzhou Hu; Rong Sheng; Honghai Wu; Difeng Zhu; Hong Zhu; Qiaojun He; Bo Yang
Journal:  Invest New Drugs       Date:  2010-06-05       Impact factor: 3.850

4.  Brain-expressed X-linked 2 Is Pivotal for Hyperactive Mechanistic Target of Rapamycin (mTOR)-mediated Tumorigenesis.

Authors:  Zhongdong Hu; Ying Wang; Fuqiang Huang; Rongrong Chen; Chunjia Li; Fang Wang; June Goto; David J Kwiatkowski; Joanna Wdzieczak-Bakala; Pengfei Tu; Jianmiao Liu; Xiaojun Zha; Hongbing Zhang
Journal:  J Biol Chem       Date:  2015-08-20       Impact factor: 5.157

5.  The chemopreventive retinoid 4HPR impairs prostate cancer cell migration and invasion by interfering with FAK/AKT/GSK3beta pathway and beta-catenin stability.

Authors:  Roberto Benelli; Stefano Monteghirfo; Roberta Venè; Francesca Tosetti; Nicoletta Ferrari
Journal:  Mol Cancer       Date:  2010-06-10       Impact factor: 27.401

6.  PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells.

Authors:  Christelle P El Haibi; Praveen K Sharma; Rajesh Singh; Paul R Johnson; Jill Suttles; Shailesh Singh; James W Lillard
Journal:  Mol Cancer       Date:  2010-04-22       Impact factor: 27.401

7.  Ganglioside GM3 Is Antiangiogenic in Malignant Brain Cancer.

Authors:  Thomas N Seyfried; Purna Mukherjee
Journal:  J Oncol       Date:  2010-06-20       Impact factor: 4.375

Review 8.  Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.

Authors:  Todd M Morgan; Theodore D Koreckij; Eva Corey
Journal:  Curr Cancer Drug Targets       Date:  2009-03       Impact factor: 3.428

9.  Interleukin-32 expression in the pancreas.

Authors:  Atsushi Nishida; Akira Andoh; Osamu Inatomi; Yoshihide Fujiyama
Journal:  J Biol Chem       Date:  2009-04-21       Impact factor: 5.157

10.  The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer.

Authors:  R Diaz; P A Nguewa; J A Diaz-Gonzalez; E Hamel; O Gonzalez-Moreno; R Catena; D Serrano; M Redrado; D Sherris; A Calvo
Journal:  Br J Cancer       Date:  2009-02-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.